About us
Despite tech advancements, bringing a new drug to market remains a decade-long, billion-dollar endeavor. The time and costs of drug development continue to climb, leading to higher drug and healthcare costs, and making treatments less accessible for many. By taking a radically more efficient approach across the drug development lifecycle, we are moving faster than ever before toward bringing treatments to patients.
From the Founder
I went into computational biology, believing that applying AI to drug discovery could help expedite drug development. However, during my graduate work, I observed that inefficient clinical development of promising drug candidates was really one of the greatest bottlenecks to resolve in forming new treatments. This compelled me to start a company where we could create the pharma company of the future driven by tech and AI, with a mission of bringing new treatments to patients faster and more efficiently.
We believe bringing the best of tech and pharma together to build a pharma company that scaleswill ultimately transform the drug development industry and increase the number of much-needed treatments available to patients. Taking on the challenges of modern medicine will require a coordinated pursuit, organized against impossible odds, and synchronized for speed.
At Formation Bio we believe bringing together diverse people from different industries will allow us to achieve this. We are a team of tech and pharma experts who deeply believe in this mission and are excited to make a difference in the industry by bringing new treatments to patients faster and more efficiently.
Join us at Formation Bio to build the pharma company of the future.
Ben Liu
CEO & Co-Founder
Our Leadership Team
Ben Liu
CEO & Co-Founder
Linhao Zhang
CTO & Co-Founder
Gavin Corcoran, MD
Chief Development Officer
James Leslie
Chief Financial Officer
Melissa Enbar
Chief People Officer
Our Investors
Formation Bio has raised capital from a range of technology and biosciences investors. Investors include Sam Altman, Michael Moritz, Sequoia Capital, Thrive Capital, Section 32, John Doerr and others.
Select Advisors
David Nicholson
Former Chief R&D Officer, Allergan
Lawrence Olanoff, MD, PhD
Former COO & President, Forest (Allergan)
June Bray
Former Sr. VP Reg Affairs, Allergan
Rehan Verjee
Former President, EMD Serono Inc.
Don DeGolyer
Former CEO, Sandoz
Ken Somberg, MD
Former CMO, Covance
Jay Parikh
Former VP of Engineering, Facebook